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OBJECTIVES: Though the greatest proportion of irritable bowel syndrome (IBS) patients report a mixed bowel
pattern (IBS-Mixed), no available therapies have been rigorously evaluated in this subgroup. This
study aimed to evaluate the efficacy and safety of the 5-HT4 agonist tegaserod in women with
IBS-Mixed and IBS with constipation (IBS-C).
METHODS: This prospective, double-blind, randomized, placebo-controlled, multicenter study was conducted in
100 centers in North America, South America, and Europe. Women with IBS-Mixed or IBS-C received
tegaserod 6 mg or placebo twice daily. The primary efficacy variable was the patient’s assessment
of satisfactory relief over the 4-wk treatment period. The proportion of patients reporting
satisfactory relief for ≥3 of 4 treatment weeks (75% rule) and individual IBS symptoms were
assessed.
RESULTS: In total, 661 women were randomized (IBS-Mixed 324, IBS-C 337). Baseline symptom assessments
identified clear differences between the two cohorts. Tegaserod provided significant improvement in
satisfactory relief of IBS symptoms over 4 wk (OR 1.75, 95% CI 1.35–2.25, P < 0.001) in both
IBS-Mixed and IBS-C patients. Using the 75% rule, 52.3% of tegaserod-receiving IBS-M patients and
43.3% of IBS-C patients were responders (vs 36.3, OR 1.88, 95% CI 1.16–3.04, P < 0.010; and
28.9, OR 1.90, 95% CI 1.19–3.05, P < 0.008 for placebo, respectively). The most frequent adverse
events leading to study discontinuation in tegaserod-treated patients were diarrhea (1.5%) and
abdominal pain (0.9%). Overall 7% of IBS-C patients reported diarrhea compared to 12% of
IBS-Mixed (placebo 2.4%, 1.8%, respectively).
CONCLUSIONS: Tegaserod is effective in treating overall IBS symptoms in patients with IBS-Mixed and
IBS-C.
(Am J Gastroenterol 2008;103:1217–1225)
INTRODUCTION
Irritable bowel syndrome (IBS) is a chronic functional gas-
trointestinal (GI) disorder characterized by recurrent abdom-
inal pain and/or discomfort in association with altered bowel
habits (1, 2). Recent estimates suggest that 10–15% of the
general population experience symptoms suggestive of IBS
(3, 4). In clinical practice, health-care providers base manage-
ment decisions upon a patient’s predominant bowel-related
symptoms. All of the recently approved IBS therapies have
been developed for the treatment of patients with IBS with
diarrhea or constipation. Unfortunately, 30–50% of IBS pa-
tients report a mixture of diarrhea and constipation (1, 5, 6).
This subgroup is now referred to as IBS with a “mixed” bowel
pattern (IBS-Mixed) (7). There have been no large, prospec-
tive methodologically rigorous studies that have evaluated the
efficacy of medical therapies in IBS-Mixed patients.
The pathophysiology of IBS remains incompletely under-
stood. Factors that appear to play a role in IBS include alter-
ations in GI motility, visceral perception, and psychosocial
factors (8, 9). Serotonin has been found to play a critical
role in GI motility, secretion, and sensation in health and
functional bowel disorders like IBS (10–12). Medical thera-
pies that target the regulation of serotonin have demonstrated
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Figure 1. Study overview. ∗More than one reason for discontinuation can be included. AEs = adverse events.
efficacy in IBS with constipation (IBS-C) (13–16) and IBS
with diarrhea (IBS-D) (17–19).
Tegaserod is an aminoguanidine-indole compound that
acts as a selective 5-HT4 receptor agonist (20). Tegaserod
augments the peristaltic reflex and accelerates orocecal and
colonic transit (21, 22). Animal and human data suggest that
tegaserod may also exert effects on visceral sensation (23–
25). Tegaserod has proven more effective than placebo at im-
proving global and individual symptoms in IBS-C patients
(13, 14, 26–28). Though tegaserod has been studied in pa-
tients with nondiarrhea IBS (26, 28), the efficacy of tegaserod
in IBS-Mixed patients has not previously been specifically
assessed.
This large, placebo-controlled study was designed to eval-
uate the efficacy and safety of tegaserod in women with IBS-
Mixed and IBS-C.
Table 1. Stratification for Randomization by the Number of Consti-
pation and Diarrhea Criteria Met
Number of Constipation Criteria Met
Number of Diarrhea
Criteria Met 0 1 2 3
0 NE IBS-C IBS-C IBS-C
1 NE IBS-Mixed IBS-C IBS-C
2 NE NE IBS-Mixed IBS-Mixed
3 NE NE IBS-Mixed IBS-Mixed
NE – indicated that the patient had either IBS-D or normal bowel habits by history and
was not eligible for the study.
IBS-C = irritable bowel syndrome (IBS) with constipation predominance; IBS-D =
IBS with diarrhea predominance.
Constipation criteria: <3 bowel movements (BMs) per week, hard or lumpy stools
and/or straining.
Diarrhea criteria: >3 BMs per day, loose/mushy or watery stools and/or urgency.
MATERIALS AND METHODS
Protocol
This was a prospective, double-blind, randomized, placebo-
controlled, parallel-group, multicenter study in women with
IBS-Mixed or IBS-C. The study comprised a 2-wk screen-
ing period (no medication or placebo), a 2-wk baseline pe-
riod to assess symptom severity (no medication or placebo),
followed by a 4-wk treatment period (Fig. 1). During the
4-wk treatment period, patients received either tegaserod
6 mg or placebo twice daily (b.i.d.). Patients were stratified
to IBS-Mixed or IBS-C based on the physician–investigator’s
assessment of their self-reported IBS symptoms using criteria
established prior to study initiation (Table 1). Patients in each
stratum (IBS-Mixed or IBS-C) were randomized to tegaserod
or placebo in a 1:1 ratio.
Visits took place at screening (day 28), the start of baseline
(day 14), and on the first and last day of the 4-wk treatment
period. On a daily basis, patients recorded their symptoms, as
well as any laxative or antidiarrheal medication intake, using
a touch-tone telephone system.
To assess primary efficacy, patients responded (yes/no)
weekly to the following question: “Over the past week, do
you consider that you have had satisfactory relief from your
symptoms of IBS?” Patients were instructed that “satisfac-
tory” relief meant that compared to their previous typical
IBS symptoms, they felt that their IBS symptoms over the
past week had been improved to an extent that they would
take a medication to maintain that state of improvement.
Patients were also asked to characterize on a daily ba-
sis their abdominal discomfort or pain, bloating, stool fre-
quency, stool consistency, straining, and urgency. Abdomi-
nal discomfort or pain and bloating were assessed using a
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7-point scale (0 = none, 1 = very mild, 2 = mild, 3 = moder-
ate, 4 = moderately severe, 5 = severe, and 6 = very severe).
Stool consistency was assessed using the Bristol Stool Form
Scale (29), ranging from 1 (separate hard lumps, like nuts) to
7 (watery, no solid pieces). Straining and urgency were
recorded using a binary scale (yes/no).
Safety assessments involved monitoring and recording all
adverse events (AEs), serious AEs, baseline assessments of
hematology and blood chemistry, and regular assessments of
vital signs, physical condition, and body weight.
Patients’ perception of study medication was also assessed
at the end of the study using a six-item questionnaire.
This study was performed in accordance with the Declara-
tion of Helsinki and the U.S. 21 Code of Federal Regulations
regarding informed patient consent and institutional review
board approval.
Setting and Participants
Women, 18–65 yr of age, with a history of IBS, exclud-
ing those with Rome II-defined IBS-D, were eligible for this
study. IBS-C was defined using the Rome II criteria (2). Pa-
tients who did not fulfill the Rome II criteria for IBS-C or
IBS-D were classified as suffering from IBS-Mixed based
on the assessment by the physician–investigator (Table 1).
Subjects with symptoms of IBS with a normal bowel pattern,
that is, no evidence of diarrhea or constipation, were excluded
from this study.
All patients were also required to meet the following IBS
Rome II classification (2): In the preceding 12 months, at
least 12 wk or more (not necessarily consecutive) of abdomi-
nal discomfort or pain with two of the following features: (a)
relieved with defecation, (b) onset associated with a change
in stool frequency, (c) onset associated with a change in stool
form. Inclusion for entry into the double-blind treatment pe-
riod was also dependent on patients’ responses to IBS symp-
tom assessments during the baseline period. Patients provid-
ing responses for 11 of 14 baseline days including the 3 days
prior to randomization, having an abdominal discomfort or
pain score of ≥3 (moderate) on a 7-point scale recorded on
at least 8 days, and having a mean stool consistency score of
≤4 on a 7-point scale (not including laxative-induced stool),
were eligible for randomization. Patients were not eligible for
randomization if they experienced watery stool during the
3 days prior to the randomization visit (unless documented to
be laxative induced) or 3 or more bowel movements (BMs)
per day during the 3 days prior to the randomization visit
(unless hard stools documented using the Bristol Stool Form
Scale) (29), took antidiarrheal medication for >2 days dur-
ing the baseline period or used any of laxatives during the
3 days prior to randomization, or took prohibited medications
(i.e., drugs affecting GI motility) during the baseline period.
Medications affecting GI motility and/or visceral perception
were not permitted during the study.
Assignment and Masking
Patients were assigned to treatment groups at the investigative
site according to a random allocation sequence, by strata. The
allocation sequence was generated by Novartis Drug Supply
Management using a validated system that automated the
random assignment of treatment to randomization numbers.
Randomization data were kept strictly confidential and all
personnel involved in this study remained blinded until the
study had been completed, the data file verified, and the pro-
tocol violations determined.
Statistical Analysis
The primary efficacy variable was the Patient’s Overall Satis-
factory Relief, a binary variable. The variable was collected
weekly (weeks 1–4). The null hypothesis was that the odds
of responding to treatment (i.e., responding “yes” to the as-
sessment) was the same on tegaserod 6 mg b.i.d. and placebo
(i.e., the odds ratio is equal to 1) over 4 wk of treatment. The
alternative hypothesis was that the odds ratio was not equal
to 1. The hypothesis was tested using a 2-sided test with a
5% significance level.
The null hypothesis was tested using a generalized linear
model with logistic regression. The response profile for sat-
isfactory relief was analyzed by a longitudinal analysis over
the 4 wk of treatment using a logistic regression model (gen-
eralized estimating equation). Besides treatment, covariates
included in the model were week, IBS stratification factor
(IBS-C or IBS-Mixed), baseline abdominal pain, age, pooled
center, prior use of tegaserod, and body mass index (BMI).
Centers were pooled prior to database lock based on geo-
graphical region. The significance of between-treatment dif-
ferences was analyzed by means of the Wald test based on
the robust estimator of the covariance matrix. The analysis
for the intention-to-treat (ITT) population was considered as
primary; however, the analysis was also performed within
each stratum (IBS-C or IBS-Mixed).
The “overall responder” definition analyzed was the pro-
portion of patients who responded at least 75% of the weeks.
This responder definition was analyzed using a logistic re-
gression model with the same covariates as in the primary
model (except week). Daily assessments were summarized
on a weekly and overall treatment basis using all available
data during that period. Between-treatment comparisons for
continuous variables were performed by means of an analysis
of covariance (ANCOVA) model with random subject effect.
Covariates in the models included treatment, week, IBS strat-
ification factor (constipation only or mixed), baseline score
or number of days (specific to the variable being analyzed),
age, pooled center, prior use of tegaserod, and BMI.
Treatment groups were also compared at day 28 (end of
treatment) with respect to the responses to their perception
of study medication, using a Cochran-Mantel-Haenszel test
adjusted for pooled centers for each item. The difference in
IBS symptoms at baseline between strata (IBS-C or IBS-
Mixed) was evaluated by performing ANOVA with the factors
stratum and pooled center for continuous variables and by
Fisher’s exact test for proportions.
The Pan method was used to calculate the sample size
based on generalized estimating equations methods un-
der the assumption of an exchangeable structure (30). The
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Table 2. Patient Demographics and Baseline Characteristics
Tegaserod 6 mg Placebo
b.i.d. (N = 329) (N = 332)
Age (yr)
Mean (SD) 40.6 (11.34) 41.6 (12.31)
Median 42.0 42.0
Race, N (%)
White 200 (60.8) 204 (61.4)
Black 6 (1.8) 12 (3.6)
Asian 2 (0.6) 1 (0.3)
Other∗ 121 (36.8) 115 (34.6)
Mean body mass index, kg/m2 25.7 25.7
Premenopausal women, N (%) 217 (66.0) 209 (63.0)
Duration of IBS symptoms (yr)
Mean (SD) 9.7 (9.4) 10.5 (9.3)
Median 6.0 8.0
Prior use of tegaserod, N (%) 40 (12.2) 43 (13.0)
b.i.d. = twice daily; SD = standard deviation; IBS = irritable bowel syndrome.
∗Other category includes 76 of 121 subjects that reported that they were Hispanic (63%).
response rate for placebo in a previous study was found to be
approximately 33% (27). Thus, this study was powered to
detect a treatment difference of 11% (or an odds ratio of
approximately 1.6). The acceptable type I error rate was es-
timated to be 5% based on a 2-sided test and the acceptable
type II error rate was 10% (i.e., power is 90%). Under these
assumptions and allowing for a dropout rate of approximately
10%, 664 randomized patients were planned.
Patients’ Perception of Study Medication
The patient’s perception of study medication was assessed
with a questionnaire that asked patients about their satisfac-
tion with and preference for the study medication relative to
symptoms of IBS and whether or not patients would use the
study medication again and would recommend it to family or
friends who have IBS.
Using the ITT population, overall treatment groups were
compared at day 28 (end of treatment) with respect to the ex-
pectation and satisfaction with the study medication as well
as to the patient’s decision to continue and recommend treat-
ment with study medication using the Mantel-Haenszel test.
A similar analysis was performed for the IBS-M and IBS-C
subgroups.
For subanalysis purposes, responses for survey questions
were dichotomized as follows: response choices 1 and 2
(i.e., “far above expectations,” and “above expectations,”
“extremely satisfied” and “satisfied”) versus other response
choices.
RESULTS
Participant Flow and Follow-Up
In total, 1,513 women from 100 primary care and gastroen-
terology centers in 11 countries, including North America,
South America, and Europe, were screened and 661 were
randomized. Patients were recruited from April 2005 until
April 2006. In total, 337 patients were included in the IBS-
Table 3. IBS Symptoms During Baseline by Strata (ITT)
IBS-C IBS-Mixed Total
(N = 337) (N = 324) (N = 661)
Mean Mean Mean
Abdominal discomfort/ 3.77 3.66 3.71
pain score∗
Bloating score∗ 3.90 3.71 3.81
No. of BMs/week§ 4.57/3.77 7.22/4.44 5.87/5.09
(mean/median)
No. of days/week 3.43 2.42 2.93
with no BMs§
Stool consistency score† 2.40 3.28 2.83
Days/week with normal 2.08 3.06 2.56
stool consistency‡,§
Days/week with straining§ 4.22 3.75 3.99
Days/week with urgency§ 1.12 2.05 1.58
∗7-point scale: 0 = none and 6 = very severe.
†7-point scale: 1 = separate hard lumps like nuts and 7 = watery, no solid pieces.
‡Defined as 3–5 inclusive.
§Normalized to 7 days.
P value <0.01 for all comparisons.
C subset and 324 patients in the IBS-Mixed subset (Fig. 1).
Of the 661 randomized patients, 624 (94.4%) completed the
study.
PATIENT DEMOGRAPHICS AND BASELINE CHAR-
ACTERISTICS. Demographic and baseline characteristics
were similar across treatment groups (Table 2). The major-
ity of patients were whites, premenopausal, and between the
ages 25 and 55 yr (mean age 41.1 yr). The median duration
of IBS symptoms was 7.0 yr.
During the baseline period, 120 (35.6%) IBS-C patients
took laxatives compared to only 54 (16.7%) IBS-Mixed pa-
tients. Compared to IBS-C patients, those with IBS-Mixed
reported a greater daily BM frequency during baseline. In
addition, IBS-Mixed patients had fewer days with no BM,
greater stool consistency, more days with normal stool con-
sistency (Bristol Stool Score 3, 4, or 5), and fewer days with
straining. Small but statistically significant differences in ab-
dominal pain and bloating were noted between groups. There
was also a greater number of patients with urgency among
IBS-Mixed patients (Table 3).
PATIENTS’ OVERALL SATISFACTORY RELIEF. The
overall odds of reporting satisfactory relief of IBS symptoms
over the 4 wk of active treatment was greater with tegaserod
than placebo (odds ratio 1.75, 95% CI 1.35–2.25, P < 0.001)
and during each of weeks 2, 3, and 4 of treatment (P < 0.001).
The number and percentage of patients who were responders
for relief of overall IBS symptoms were significantly higher in
the tegaserod group compared with placebo overall and dur-
ing weeks 2, 3, and 4. Subgroup analyses by strata showed the
odds of responding were significantly greater in the tegaserod
group for IBS-Mixed patients over the 4-wk treatment period
(odds ratio 1.50, 95% CI 1.03–2.19, P = 0.034) and at weeks
2 and 4. For IBS-C patients, tegaserod led to significant im-
provements over the 4-wk treatment period (odds ratio 1.97,
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Table 4. Patients’ Assessment of Satisfactory Relief by Strata (ITT Patients)
Tegaserod 6 mg Placebo
b.i.d. N = 329 N = 332 Odds 95% CI of
Week n/m (%) n/m (%) Ratio Odds Ratio P Value
IBS-C
1 76/168 (45.2) 53/158 (33.5) 1.60 (1.01–2.55) 0.047
2 88/165 (53.3) 56/152 (36.8) 1.98 (1.24–3.17) 0.004
3 98/162 (60.5) 58/151 (38.4) 2.49 (1.57–3.95) <0.001
4 93/159 (58.5) 63/146 (43.2) 1.89 (1.19–3.00) 0.007
Overall 1.97 (1.39–2.81) <0.001
IBS-Mixed
1 74/151 (49.0) 72/159 (45.3) 1.10 (0.68–1.79) 0.698
2 92/148 (62.2) 69/157 (43.9) 2.00 (1.23–3.23) 0.005
3 84/144 (58.3) 77/153 (50.3) 1.28 (0.80–2.07) 0.306
4 85/134 (63.4) 65/140 (46.4) 1.87 (1.13–3.09) 0.015
Overall 1.50 (1.03–2.19) 0.034
n = number of patients with satisfactory relief.
m = number of patients assessed.
95% CI 1.39–2.81, P < 0.001) and at each of the 4 wk (Table
4).
The percentage of patients who experienced satisfac-
tory relief of IBS symptoms in at least 3 of 4 wk of
treatment (75% rule) was significantly higher in patients
treated with tegaserod compared with placebo in ITT pa-
tients (47.5% vs 32.6%, P < 0.001) and in both the IBS-
Mixed and IBS-C subsets (Fig. 2). The number needed to
treat (NNT) based on these response rates was 7.0 (95%
CI 4.6–14.3).
IBS SYMPTOMS OVER THE ENTIRE TREATMENT PE-
RIOD. For the IBS-Mixed group, there were statistically
significant differences between the tegaserod and placebo
groups for stool frequency (<0.001), number of days with
no BMs (0.001), stool consistency (<0.001), number of days
with straining (0.023), and number of days with urgency
(0.030). For the IBS-C group, statistically significant dif-
ferences between groups were observed for stool frequency
(<0.001), number of days with no BMs (0.020), stool con-























   = 16.0






















    = 14.4
P  = 0.008
IBS-C = irritable bowel syndrome with constipation predominance. 
Figure 2. Responder rates for patients’ overall satisfactory relief (75% rule). IBS-C = irritable bowel syndrome with constipation predomi-
nance.
SAFETY AND TOLERABILITY. Overall, 28% of patients
experienced at least one AE during treatment. The most fre-
quently reported AEs with tegaserod were diarrhea (9.4%),
headache (5.5%), abdominal pain (3.0%), and nausea (2.1%).
For patients who received placebo, the most prevalent AEs
were diarrhea (2.1%), headache (6.6%), abdominal pain
(2.1%), and nausea (3.3%). For patients with IBS-Mixed, the
most frequent AEs were diarrhea, headache, nausea, abdom-
inal pain, and abdominal distension (Table 6).
During treatment, 13.7% of patients who received
tegaserod and 9.4% of patients who received placebo had
AEs suspected to be related to study drug. Of the individual
AEs suspected to be related to study drug, only diarrhea oc-
curred more frequently in the tegaserod group compared with
placebo (7.0% vs 1.2%). In comparison, AEs reported for
diarrhea overall (regardless of relationship to study medica-
tion) were for IBS-Mixed, 12.1% of those receiving tegaserod
compared to 1.8% in the placebo group, and for 7% of IBS-C
patients randomized to tegaserod compared to 2.4% of those
receiving placebo.
Seventy-nine percent of tegaserod patients who experi-
enced their first episode of diarrhea reported as an AE did so
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Table 5. IBS Symptoms Over the Entire Treatment Period (ITT Patients)
IBS-Mixed IBS-C
Tegaserod Tegaserod
Assessment 6 mg b.i.d. Placebo P Value 6 mg b.i.d. Placebo P Value
Abdominal discomfort/pain 2.66 2.83 0.310 2.84 2.95 0.588
Bloating 2.83 2.99 0.303 3.08 3.16 0.335
No. of bowel movements∗ 9.78 8.34 <0.001 6.88 6.06 <0.001
No. of days with no bowel movements∗ 1.39 1.68 0.001 2.31 2.48 0.020
Stool consistency 3.95 3.49 <0.001 3.53 2.89 <0.001
No. of days with normal stool consistency∗† 3.90 3.91 0.731 3.69 3.39 0.120
No. of days with straining∗ 2.42 2.87 0.023 3.08 3.55 0.018
No. of days with urgency∗ 2.01 1.88 0.030 1.37 1.16 0.057
Mean values are presented, unless noted.
∗Normalized to 7 days.
†Normal stool consistency is defined as stool consistency score 3–5 inclusive.
ITT = intention-to-treat; IBS-C = irritable bowel syndrome with constipation predominance; b.i.d. = twice daily.
during days 1–7 of treatment, as compared to 57% of placebo
patients. The mean duration of diarrheal episodes was longer
in the tegaserod group than the placebo group. Subjects in
both the IBS-C and IBS-M cohorts reported similar findings
in regards to diarrhea onset, duration, and severity. There were
no significant differences in episodes of diarrhea reported as
AEs in patients with IBS-Mixed (23 tegaserod, 4 placebo)
and patients with IBS-C (18 tegaserod, 5 placebo).
Other AEs suspected to be treatment related that occurred
in ≥2% of patients were abdominal pain (2.7% in tegaserod
vs 1.8% in placebo) and headache (2.4% in tegaserod vs 3.0%
in placebo). Similar results were reported in the IBS-Mixed
and the IBS-C subsets.
Discontinuation due to AEs occurred in 1.8% of tegaserod-
treated patients and 3.0% of placebo-treated patients. The
AEs that most commonly led to discontinuation were diar-
rhea (1.5% for tegaserod and 0.6% for placebo), abdominal
pain (0.9% tegaserod vs 0.6% placebo), and headache (0.3%
tegaserod vs 0.9% placebo). In the IBS-Mixed subset, 2.5%
of tegaserod-treated patients and 0.6% of placebo-treated
patients discontinued because of diarrhea. In patients with
Table 6. Frequency of Reported AEs (>1% Total in Any IBS Subgroup) by IBS Subgroup and Treatment
IBS-Mixed IBS-C
Tegaserod Tegaserod
6 mg b.i.d. Placebo Total 6 mg b.i.d. Placebo Total
N = 157 N = 167 N = 324 N = 172 N = 164 N = 336
N (%) N (%) N (%) N (%) N (%) N (%)
Any preferred term 51 (32.5) 41 (24.6) 92 (28.4) 46 (26.7) 44 (26.8) 90 (26.8)
Diarrhea 19 (12.1) 3 (1.8) 22 (6.8) 12 (7.0) 4 (2.4) 16 (4.8)
Headache 10 (6.4) 14 (8.4) 24 (7.4) 8 (4.7) 8 (4.9) 16 (4.8)
Abdominal pain 5 (3.2) 3 (1.8) 8 (2.5) 5 (2.9) 4 (2.4) 9 (2.7)
Influenza 2 (1.3) 3 (1.8) 5 (1.5) 3 (1.7) 2 (1.2) 5 (1.5)
Back pain 2 (1.3) 1 (0.6) 3 (0.9) 2 (1.2) 2 (1.2) 4 (1.2)
Abdominal distension 3 (1.9) 2 (1.2) 5 (1.5) 0 (0) 4 (2.4) 4 (1.2)
Nasopharyngitis 1 (0.6) 0 (0) 1 (0.3) 0 (0) 4 (2.4) 4 (1.2)
Nausea 7 (4.5) 4 (2.4) 11 (3.4) 0 (0) 7 (4.3) 7 (2.1)
Denominator used in the percentage calculations: patients in the safety population.
b.i.d. = twice daily.
IBS-C, diarrhea led to discontinuation in 0.6% of tegaserod-
treated patients and 0.6% of placebo-treated patients.
No deaths occurred during the study. Only two serious AEs
were reported, both in the IBS-Mixed subset (costochondritis
in a patient receiving tegaserod and appendicitis in a patient
receiving placebo), and neither event was felt to be related to
study treatment. No cases of ischemic colitis were reported.
PATIENTS’ PERCEPTION OF STUDY MEDICATION. A
significantly greater proportion of ITT patients treated with
tegaserod than placebo considered relief of their symptoms
far above/above expectations (33.6% vs 20.7%, P = 0.001). A
statistically significantly higher percentage of patients treated
with tegaserod than placebo were extremely satisfied/satisfied
with their treatment (55.3% vs 41.9%, P = 0.02). In addition,
a significantly greater percentage of tegaserod patients than
placebo patients said they would recommend their medica-
tion to family or friends with IBS (71.4% vs 60.8%, P =
0.007). More IBS-Mixed patients on tegaserod than placebo
considered that the study medication was far above/above
expectations (36.7% vs 21.5%, P = 0.051).
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DISCUSSION
The results of this large, multinational, randomized, placebo-
controlled study show that tegaserod effectively relieved over-
all symptoms and was well tolerated in patients with IBS-M.
The study population included patients with IBS symptoms
and symptoms of diarrhea and/or constipation. Patients with
IBS and a normal bowel pattern, that is, no criteria for diar-
rhea or constipation, were excluded. Though tegaserod has
previously been studied in patients with “nondiarrhea” IBS
(26, 28), the design of these trials did not allow a specific anal-
ysis of treatment efficacy in patients with IBS-Mixed. Unlike
these previous trials with tegaserod, the design of the current
trial allowed us to clearly demonstrate benefits of tegaserod
in patients with IBS-Mixed as well as IBS-C. This is one of
the first studies to identify an efficacious medical therapy for
this challenging subset of IBS sufferers.
IBS is a disorder of heterogeneous pathogenesis and
symptom expression. According to the Rome criteria, all
patients with IBS experience some degree of abdominal
pain or discomfort. However, bowel-related symptoms are
highly variable with some patients endorsing predominantly
constipation-related complaints (reduced stool frequency,
hard or lumpy stools, straining to pass a BM), others report-
ing a predominance of diarrhea-related complaints (increased
stool frequency, decreased stool consistency, or urgency), and
still others reporting a mixture of constipation and diarrhea-
related complaints. Epidemiological studies have reported
that 30–50% of IBS sufferers do not fulfill diagnostic criteria
for IBS-C or IBS-D. In fact, most studies have reported that
the greatest proportion of IBS patients fits into the IBS-Mixed
category (1, 5, 6). Recent work suggests that the clinical char-
acteristics of IBS-Mixed more closely resemble IBS-C than
IBS-D (1, 5, 6). In addition, “natural history” studies suggest
that there is migration of IBS patients from one subgroup to
another and that the IBS-Mixed subgroup is the least stable.
Further, migration between IBS-C and IBS-Mixed appears to
occur more commonly than between IBS-D and IBS-Mixed
or IBS-C (1).
Despite being the most prevalent subgroup of IBS, the
management of patients with IBS-Mixed is less well defined
than for IBS-C or IBS-D patients. There are currently no med-
ical therapies that have been rigorously evaluated in patients
with IBS-Mixed. Not surprisingly then, there are currently
no therapies that have been approved in the United States or
elsewhere for this IBS subgroup.
The literature addressing the IBS-Mixed group is chal-
lenging to interpret related to inherent differences in study
populations and the varied definitions of IBS-Mixed used in
the different studies. Formal criteria for IBS-Mixed have re-
cently been published as part of the Rome III process (7).
Unfortunately, the Rome III criteria were not available at the
time this study was designed. In this study, IBS was defined
using the Rome II criteria (2). While Rome II offered criteria
for defining IBS-C and IBS-D, there was no recommenda-
tion for IBS-Mixed (2). After excluding patients with normal
bowel habits, we defined IBS-Mixed as those patients who
did not fulfill the Rome II criteria for IBS-C or IBS-D.
Using these definitions, we found clear clinical differ-
ences between the IBS-Mixed and IBS-C subgroups during
the 2-wk baseline period, supporting the notion that they in-
deed represent distinct patient subgroups. In the absence of
any drug interventions, patients with IBS-Mixed reported
a greater daily stool frequency, fewer days without a BM,
a higher stool consistency score on the Bristol Stool Form
Scale, more days with a normal stool consistency, and fewer
days without straining compared to IBS-C patients. There
were also a greater number of patients with urgency among
IBS-Mixed patients. There were statistically significant dif-
ferences in abdominal pain/discomfort and bloating scores
between the IBS-Mixed and IBS-C subgroups, though the
clinical relevance of these small differences is questionable.
Results from this study indicate that tegaserod was more
effective than placebo at improving the patient’s assessment
of overall satisfactory relief in patients with IBS-M. The num-
ber and percentage of patients who were responders for re-
lief of overall IBS symptoms were significantly higher in the
tegaserod than the placebo group. Overall, a higher percent-
age of tegaserod patients achieved overall satisfactory relief
compared with placebo at each week of treatment.
Tegaserod provided satisfactory relief of IBS symptoms
in more patients than placebo for subsets of patients with
IBS-Mixed and IBS-C. The percentage of tegaserod patients
achieving satisfactory relief was statistically significantly
higher at weeks 2 and 4, and overall in patients with IBS-
Mixed and at all weeks and overall in patients with IBS-C.
Patients with IBS-Mixed and IBS-C treated with tegaserod
had significantly more BMs, fewer days with no BMs, a
higher stool consistency score, fewer days with straining, and
a higher number of days with urgency than those randomized
to placebo. No differences were observed in mean abdominal
discomfort and pain scores and mean bloating scores between
the tegaserod and placebo groups.
Given the baseline differences in clinical characteristics
between patients with IBS-Mixed and IBS-C, a review of
AEs reported in association with tegaserod is of consider-
able interest. Similar to previous studies, the most commonly
reported AE in association with tegaserod was diarrhea. Di-
arrhea in patients taking tegaserod tended to occur during the
first week of therapy and usually was transient. Only 1.5%
of tegaserod-treated subjects discontinued therapy due to di-
arrhea. In addition, there were no clinically relevant conse-
quences (hospitalization, fluid and electrolyte imbalance, or
dehydration) reported due to diarrhea.
An issue worthy of discussion is the duration of the trial.
Most previous trials with tegaserod have employed random-
ized treatment periods of 12 wk. This trial employed a ran-
domized treatment period of 4 wk. The Rome III recommen-
dations on the design of treatment trials for functional GI
disorders (31) suggest that trial duration should be based on
the natural history of symptomatic episodes for the disorder
in question. The Rome III document also points out that the
1224 Chey et al.
European Agency for the Evaluation of Medicinal Products
(EMEA) is accepting 4-wk trials when considering short-
term efficacy indications. For these reasons, we feel that the
data generated by this trial offer information that is relevant
to the treatment of IBS-Mixed and IBS-C patients.
In conclusion, IBS-Mixed and IBS-C patients can be dis-
tinguished by differences in bowel-related symptoms such
as stool frequency, stool consistency, straining, and urgency.
Tegaserod 6 mg b.i.d. for 4 wk was more effective than
placebo in relieving the symptoms of IBS in women with
either IBS-Mixed or IBS-C. Tegaserod was well tolerated in
these IBS populations. Tegaserod offers a viable treatment
option for women with IBS and a mixed bowel pattern.
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STUDY HIGHLIGHTS
What Is Current Knowledge
 The largest proportion of irritable bowel syndrome
(IBS) patients suffer with a mixture of constipation
and diarrhea (IBS with a mixed bowel pattern [IBS-
Mixed]).
 No available treatments have been specifically evalu-
ated in patients with IBS-Mixed.
 Tegaserod is more effective than placebo for global and
individual symptoms in patients with IBS with consti-
pation (IBS-C).
What Is New Here
 Compared to IBS-C, IBS-Mixed patients reported
greater stool frequency, differences in stool consis-
tency, less straining, and more urgency.
 Tegaserod 6 mg b.i.d. was more effective than placebo
in relieving IBS-Mixed.
 Diarrhea was the most common adverse event and was
reported in 12% of IBS-Mixed and 7% of IBS-C pa-
tients.
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